Theratechnologies Inc T.TH

PLWH have twofold risk of liver fibrosis

[scarlet1967]

Tesamorelin has been tested on HIV liver (which is harder to treat than none HIV liver due to ART and other factors) so far and the company strongly believe they can achieve better results on general population.
https://www.aidsmap.com/news/jan-2021/middle-aged-people-hiv-and-no-hepatitis-co-infection-have-twofold-increase-risk-liver

[scarlet1967]

https://www.futuremedicine.com/doi/abs/10.2217/fvl-2020-0184?journalCode=fvl  

[palinc2000]

Do you recall how big the subgroup of Hiv patiemnts will be included in the Nash trial?I think there could be a chance that FDA could allow a Label Extension for Nash HIV patients when the DSMB carries oiut an interim review .....Am I dreaming?

[scarlet1967]

They said initially min 50 HIV cohorts will be included in the trial. As per their estimates some 20% in the US suffer from NAFLD and 3 to 12% from NASH in the US . As per global liver institute/NASH council the comorbidity of none adavanced NASH and other conditions such as diabetes type 2 increased the cost to US healthcare in 2017 from $222 billion to $667 billion! The prevalence of liver